[3]
WHO. Global tuberculosis report, 2017.
[6]
World health organization , Multidrug and extensively drug resistance
Tb (M/XDR-TB): 2010 Global report on surveillance and
response.,
[7]
WHO treatment guidelines for drug-resistant tuberculosis, 2016.
[22]
Katherine, A. Identification of Novel Imidazo[1,2-a]pyridine Inhibitors
Targeting M. tuberculosis.QcrB., 2012 Jul 12;52951
[35]
Fillingame, R.H. The Bacteria., 1990, Vol. XII, 345-391.
[40]
Valiyaveetil, F.; Fillingame, R.H. On the Role of Arg-210 and Glu-
219 of Subunit a in Proton Translocation by the Escherichia coli
F0F1-ATP Synthase. 1997, 272,(51), 32635-32641.
[42]
Guillemont, J. Patent (International Publication Number: WO
2004/011436 International Publication Date, 2004 Feb 5;.
[47]
Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci. Adv., 2014, Nov 28; 204-384.
[49]
Mesens, N.; Verbeeck, J.; Rouan, M.; Vanparys, P. Elucidating the
role of M2 in the preclinical safety profile of TMC207. Abstract on
the 38th Union World Conference on Lung Health, 2007.Cape
Town, South Africa
[52]
Singh, S.; Roy, K.K.; Khan, S.R.; Kashyap, V.; Sharma, A.; Jaiswal, S.; Sharma, S.K.; Krishnan, M.Y.; Chaturvedi, V.; Lal, J.; Sinha, S.; Gupta, A.D.; Srivastava, R.; Saxena, A.K. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non- replicating M. tuberculosis. Bioorg. Med. Chem., 2015, 23(4), 742-752.
[53]
Kaliaa, D.; Kumar, A.; Meenaa, G.; Sethia, K.P.; Sharma, R.; Trivedi, P.; Khan, S.R.; Singh, A.; Singh, A.S.; Sharma, S.; Roy, K.K.; Kant, R.; Krishnan, M.Y.; Singh, B.N.; Sinha, S.; Chaturvedi, V Synthesis and anti-tubercular activity of conformationally constrained
and bisquinoline analogs of TMC207, Med. Chem.
Commun. 2015, 1554-1563.
[72]
George, S.K.; Thengungal, R. Design, synthesis and antitubercular screening of certain novel thiadiazolyl pyrrolidine carboxamides as enoyl ACP reductase inhibitors. Int. J. Pharm. Pharm. Sci., 2011, 3, 280-284.
[76]
Ballell Pages, L.; Castro Pichel, J.; Fernandez Menendez, R.; Fernandez Velando, E. P.; Gonzalez Del Valle, S.; Mendoza Losana, A.; Wolfendale, M. J. (Pyrazol-3-yl)-1,3,4-thiadiazole-2-amine
an(Pyrazol-3-yl)-1,3,4-thiazole-2-amine Compounds. PCT publication
No.(Pyrazol-3-yl)-1,3,4-thiadiazole-2-amine an(Pyrazol-3-yl)-
1,3,4-thiazole-2-amine Compounds. PCT publication No. WO
2010/118852 A1, 2010.
[77]
Castro Pichel, J.; Fernandez Menendez, R.; Fernandez Velando, E. P.; Gonzalez Del Valle, S.; Mallo-Rubio, A. 3-Amino- PyrazoleDerivatives Useful Against Tuberculosis. PCT publication No. WO2012/049161 A1,, 2012.
[83]
Satpati, S.; Behera, P.; Dixit, A. Identification of Lip Y inhibitors as antitubercular agents using stepwise virtual screening. IJPCBS, 2016, 6, 400-413.
[99]
Naik, M.; Humnabadkar, V.; Tantry, S.J.; Panda, M.; Narayan, A.; Guptha, S.; Panduga, V.; Manjrekar, P.; Jena, L.K.; Koushik, K.; Shanbhag, G.; Jatheendranath, S.; Manjunatha, M.R.; Gorai, G.; Bathula, C.; Rudrapatna, S.; Achar, V.; Sharma, S.; Ambady, A.; Hegde, N.; Mahadevaswamy, J.; Kaur, P.; Sambandamurthy, V.K.; Awasthy, D.; Narayan, C.; Ravishankar, S.; Madhavapeddi, P.; Reddy, J.; Prabhakar, K.; Saralaya, R.; Chatterji, M.; Whiteaker, J.; McLaughlin, B.; Chiarelli, L.R.; Riccardi, G.; Pasca, M.R.; Binda, C.; Neres, J.; Dhar, N.; Signorino-Gelo, F.; McKinney, J.D.; Ramachandran, V.; Shandil, R.; Tommasi, R.; Iyer, P.S.; Narayanan, S.; Hosagrahara, V.; Kavanagh, S.; Dinesh, N.; Ghorpade, S.R. 4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
J. Med. Chem., 2014,
57(12), 5419-5434.
[
http://dx.doi.org/10.1021/jm5005978] [PMID:
24871036]
[103]
Katzung, S.M.B.G.; Trevor, A.J. Basic and Clinical Pharmacology, 11th ed; , 2009.
[110]
ClinicalTrials.gov, in clinicaltrials.gov, accessed, 2017 Mar 03;
[111]
ClinicalTrials.gov, in clinicaltrials.gov, accessed. 2018 Mar 03;